Sheaff Brock Investment Advisors LLC reduced its stake in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 55.1% during the first quarter, HoldingsChannel reports. The firm owned 2,157 shares of the company’s stock after selling 2,650 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Moderna were worth $372,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of MRNA. Norges Bank purchased a new stake in Moderna during the 4th quarter valued at about $773,229,000. Theleme Partners LLP lifted its position in Moderna by 26.9% in the fourth quarter. Theleme Partners LLP now owns 5,022,174 shares of the company’s stock valued at $1,275,532,000 after purchasing an additional 1,065,100 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Moderna by 76.2% during the fourth quarter. The Manufacturers Life Insurance Company now owns 2,180,819 shares of the company’s stock valued at $553,310,000 after purchasing an additional 943,271 shares during the period. Invesco Ltd. grew its holdings in shares of Moderna by 108.5% in the fourth quarter. Invesco Ltd. now owns 1,756,941 shares of the company’s stock worth $446,229,000 after purchasing an additional 914,343 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Moderna by 6.5% in the fourth quarter. State Street Corp now owns 14,863,370 shares of the company’s stock worth $3,774,999,000 after buying an additional 905,789 shares during the period. 61.20% of the stock is owned by hedge funds and other institutional investors.
Moderna Stock Up 4.1 %
Shares of NASDAQ MRNA opened at $194.18 on Friday. The company has a current ratio of 1.99, a quick ratio of 1.56 and a debt-to-equity ratio of 0.04. The firm has a fifty day simple moving average of $151.55 and a two-hundred day simple moving average of $152.84. The firm has a market capitalization of $77.24 billion, a PE ratio of 5.92, a price-to-earnings-growth ratio of 1.05 and a beta of 1.61. Moderna, Inc. has a 12 month low of $115.61 and a 12 month high of $497.49.
Analyst Ratings Changes
A number of equities research analysts recently commented on the stock. Piper Sandler lowered their price target on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a report on Tuesday, May 17th. Morgan Stanley lowered their price target on shares of Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a report on Thursday. Finally, SVB Leerink upped their price target on shares of Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $226.92.
Insider Buying and Selling
In related news, insider Juan Andres sold 195 shares of the stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $133.71, for a total value of $26,073.45. Following the completion of the transaction, the insider now directly owns 9,309 shares in the company, valued at approximately $1,244,706.39. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Juan Andres sold 195 shares of the stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $133.71, for a total transaction of $26,073.45. Following the sale, the insider now directly owns 9,309 shares of the company’s stock, valued at approximately $1,244,706.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $130.74, for a total transaction of $1,307,400.00. Following the sale, the director now directly owns 2,229,673 shares in the company, valued at $291,507,448.02. The disclosure for this sale can be found here. Insiders sold a total of 554,029 shares of company stock worth $82,263,545 in the last three months. 17.30% of the stock is owned by corporate insiders.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- BJ’s Wholesale Club Stock Has More Room to Grow
- How Does Freeport McMoran Inc Compare to Its Sector Competitors?
- 3 Hotel Stocks to Consider Checking into After Earnings
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.